HONG KONG — A small molecule has been shown to be capable of breaking down amyloid beta deposits in a study of the brains of mice exhibiting the symptoms of Alzheimer's disease (AD), an important finding that may lead to the development of new treatments for the different stages of AD, according to the results of a study by Korean researchers.
SHANGHAI – Beijing-based Beigene Co. Ltd. has shared positive phase I results for BGB-3111, a targeted small-molecule BTK inhibitor to treat B-cell malignancies that Beigene execs believe has the potential to become best in class, beating out ibrutinib (Imbruvica, Pharmacyclics Inc./Johnson & Johnson), the only BTK inhibitor currently on the market in the U.S. and Europe.
Astellas Pharma Inc., of Tokyo, said results from the pivotal phase III SECURE trial evaluating Cresemba (isavuconazonium sulfate) in adult patients with invasive aspergillosis were published in The Lancet. The article, "Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial," appears in the Dec. 9 online issue.
HONG KONG – Chinese biopharma company Huya Bioscience International LLC extended its global partnership and commercialization business model to South Korea, looking to replicate the success it has had taking promising compounds from one country – mostly China – and developing them elsewhere.
HONG KONG – Australian researchers led by the University of New South Wales (UNSW) have discovered the mechanism whereby synaptic connections between brain cells are destroyed in the early stages of Alzheimer's disease (AD), a key finding that clears the way for new research on urgently needed treatments for the currently incurable degenerative brain disease.
NEW DELHI – Indian generics drugmaker Cipla Ltd. said it will explore all legal options available after an Indian court's recent ruling that the firm infringed the patent rights of Swiss drug major Roche AG regarding lung cancer drug erlotinib.
SHANGHAI – In what could be called a surprising about-face, Eisai Co. Ltd. has bought itself a small piece of China's generic market with the acquisition of Liaoning Tianyi Biological Pharmaceutical Co. Ltd., for $78.2 million. Eisai's execs said they are hoping to take advantage of a segment they believe will see robust growth in the coming years in China: high-quality generic drugs.
SHANGHAI – Getting a drug to patients in China's huge, fractured market is no easy task. But it is a challenge China's state-owned firm, Sinopharm Group, happens to have well under control: It is China's biggest drug distributor, and, not surprisingly, it is the first firm in China's health care sector to make the Fortune 500 list. Last year, Sinopharm's revenues topped $30 billion.
HONG KONG – Three-year old Chinese novel monoclonal antibody (MAb) developer Akeso Biopharma Inc. has signed a $200 million deal with MSD China, out-licensing its first compound. The deal comes on the heels of closing a $20 million series A financing funded by local investors.
RSS